REG - RTW Biotech Opp. - Total Voting Rights

RTW Biotech OpportunitiesAnnouncement

01/05/2026 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA6743Ca&default-theme=true

RNS Number : 6743C  RTW Biotech Opportunities Ltd  01 May 2026

LEI: 549300Q7EXQQH6KF7Z84

1 May 2026

RTW Biotech Opportunities Ltd
(the "Company")

Total Voting Rights

In accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and
Transparency Rules, the Company notifies the following:

 

As at the close of business on 30 April 2026, the Company had 345,967,440
Ordinary Shares in issue, of which 22,320,003 were held in treasury.
Therefore, the total number of voting rights in the Company at that date was
323,647,437.

 

The above figure of 323,647,437 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6362

 Oliver Kenyon (Business & Corporate Development)       biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune (Investor Relations)

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com (http://www.rtwbio.com)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking statements
are subject to risks, uncertainties and assumptions, and therefore the events
in the forward-looking statements may not occur.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQBLFXQZLBBBV



            Copyright 2019 Regulatory News Service, all rights reserved